QUALITY OF LIFE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER: AN IRONMAN REGISTRY ANALYSIS
Author(s)
Divyan Chopra, PhD1, Emma C. Martin, PhD2, Katie Frampton, MSc2, Mike Greenwood, BSc2, Kim Cocks, PhD2, Victoria L. Robinson, PhD3, Jake Vinson, MD4, Daniel George, MD5, Philip W. Kantoff, MD6, Lorelei Mucci, ScD, MPH7, Joaquin Mateo, MD8, Kim Chi, MD9, Deborah Enting, MBBS, MSc10, Ian D. Davis, MBBS, PhD11, Anders Bjartell, MD, PhD, FEBU12, Aurelius Omlin, MD13, Kjell Russnes, MD, PhD14, Ray McDermott, MD, PhD15, Andre Fay, MD, PhD16, Charles Waihenya, MBChB, MMED17, Ademola Popoola, MD18, Simone Badal, MD19, Jack Lazarus, MD20, Camille Ragin, PhD, MPH21, Folakemi Odedina, PhD22, Natalie Greaves, MBBS PhD23, Simon Anderson, MBBCh. PHD24, Björn Stollenwerk, PhD25;
1Amgen, Thousand Oaks, CA, USA, 2Adelphi Values, Bollington, United Kingdom, 3Amgen Inc, Thousand Oaks, CA, USA, 4Prostate Cancer Clinical Trials Consortium, New York, NY, USA, 5Duke Cancer Institute, Durham, NC, USA, 6Convergent Therapeutics, Cambridge, MA, USA, 7Harvard T.H. Chan School of Public Health, Boston, MA, USA, 8Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 9BC Cancer - Vancouver Centre, University of British Columbia, Vancouver, BC, Canada, 10Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 11Monash University Eastern Health Clinical School, Melbourne, Australia, 12Skåne University Hospital, Malmö, Sweden, 13Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland, 14Oslo University Hospital, Oslo, Norway, 15St Vincent’s University Hospital & University College, Dublin, Ireland, 16PUCRS School of Medicine, Porto Alegre - RS, Brazil, 17University of Nairobi, Nairobi, Kenya, 18University of Ilorin Teaching Hospital, Ilorin, Nigeria, 19The University of the West Indies, Kingston, Jamaica, 20University of Cape Town, Cape Town, South Africa, 21Fox Chase Cancer Center, Philadelphia, PA, USA, 22Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA, 23The University of the West Indies, Cave HIl, Barbados, 24The University of the West Indies, Cave Hill, Barbados, 25Amgen (Europe) GmbH, Rotkreuz, Switzerland
1Amgen, Thousand Oaks, CA, USA, 2Adelphi Values, Bollington, United Kingdom, 3Amgen Inc, Thousand Oaks, CA, USA, 4Prostate Cancer Clinical Trials Consortium, New York, NY, USA, 5Duke Cancer Institute, Durham, NC, USA, 6Convergent Therapeutics, Cambridge, MA, USA, 7Harvard T.H. Chan School of Public Health, Boston, MA, USA, 8Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, 9BC Cancer - Vancouver Centre, University of British Columbia, Vancouver, BC, Canada, 10Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 11Monash University Eastern Health Clinical School, Melbourne, Australia, 12Skåne University Hospital, Malmö, Sweden, 13Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland, 14Oslo University Hospital, Oslo, Norway, 15St Vincent’s University Hospital & University College, Dublin, Ireland, 16PUCRS School of Medicine, Porto Alegre - RS, Brazil, 17University of Nairobi, Nairobi, Kenya, 18University of Ilorin Teaching Hospital, Ilorin, Nigeria, 19The University of the West Indies, Kingston, Jamaica, 20University of Cape Town, Cape Town, South Africa, 21Fox Chase Cancer Center, Philadelphia, PA, USA, 22Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA, 23The University of the West Indies, Cave HIl, Barbados, 24The University of the West Indies, Cave Hill, Barbados, 25Amgen (Europe) GmbH, Rotkreuz, Switzerland
OBJECTIVES: Prostate cancer is the most commonly diagnosed cancer among men in the USA, accounting for over 7% of cancer diagnoses globally. Metastatic castration-resistant prostate cancer (mCRPC) is associated with substantial morbidity and mortality. This study reports real-world health-related quality-of-life (HRQoL) among patients with mCRPC from the international registry for men with advanced prostate cancer (IRONMAN) registry across 15 countries.
METHODS: HRQoL was evaluated using EORTC QLQ-C30 (global health status [GHS], physical functioning [PF]) and BPI-SF (worst pain, average pain) collected at enrolment and every three months. Subgroups were defined by first treatment received post-enrolment (taxane chemotherapy [TC] or androgen receptor pathway inhibitor [ARPI] monotherapy), and stratified by prior TC exposure. Demographic, clinical characteristics and PRO scores over time were summarised descriptively.
RESULTS: 1084 patients with mCRPC at enrolment were included (mean age: 71 years, PSA: less than 10ng/ml (54%) vs 10-20ng/ml (12%), region: 33% USA, 42% Europe). 620 of the 1084 patients received treatments post-enrolment; 91 initiated TC and 167 initiated ARPI with evaluable baseline and follow-up HRQoL assessments. Prior to treatment, TC patients reported lower HRQoL scores and higher pain scores compared to ARPI treated patients. Mean (95% CI) GHS was 65.3 (60.3-70.3) for TC versus 70.7 (67.6-73.8) for ARPI; PF was 78.4 (73.9-82.9) versus 82.8 (79.8-85.7), respectively. Baseline pain was higher in the TC group (worst-pain: 3.3 [2.8-3.7]) versus ARPI (2.7 [2.4-3.1]). HRQoL and pain score trajectories were similar between the two treatment groups, and remained relatively stable during the 6 months follow-up. Stratification by prior TC exposure also showed similar PRO trajectories.
CONCLUSIONS: In this real-world analysis, self-reported disease burden was considerable for mCRPC, and more pronounced for those initiating taxane-chemotherapy. HRQoL trajectories remained stable during follow-up with no observable improvement in key domains, emphasizing the need for improved treatment options for mCRPC.
METHODS: HRQoL was evaluated using EORTC QLQ-C30 (global health status [GHS], physical functioning [PF]) and BPI-SF (worst pain, average pain) collected at enrolment and every three months. Subgroups were defined by first treatment received post-enrolment (taxane chemotherapy [TC] or androgen receptor pathway inhibitor [ARPI] monotherapy), and stratified by prior TC exposure. Demographic, clinical characteristics and PRO scores over time were summarised descriptively.
RESULTS: 1084 patients with mCRPC at enrolment were included (mean age: 71 years, PSA: less than 10ng/ml (54%) vs 10-20ng/ml (12%), region: 33% USA, 42% Europe). 620 of the 1084 patients received treatments post-enrolment; 91 initiated TC and 167 initiated ARPI with evaluable baseline and follow-up HRQoL assessments. Prior to treatment, TC patients reported lower HRQoL scores and higher pain scores compared to ARPI treated patients. Mean (95% CI) GHS was 65.3 (60.3-70.3) for TC versus 70.7 (67.6-73.8) for ARPI; PF was 78.4 (73.9-82.9) versus 82.8 (79.8-85.7), respectively. Baseline pain was higher in the TC group (worst-pain: 3.3 [2.8-3.7]) versus ARPI (2.7 [2.4-3.1]). HRQoL and pain score trajectories were similar between the two treatment groups, and remained relatively stable during the 6 months follow-up. Stratification by prior TC exposure also showed similar PRO trajectories.
CONCLUSIONS: In this real-world analysis, self-reported disease burden was considerable for mCRPC, and more pronounced for those initiating taxane-chemotherapy. HRQoL trajectories remained stable during follow-up with no observable improvement in key domains, emphasizing the need for improved treatment options for mCRPC.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR55
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Oncology